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Abstract
Background: Irritable bowel syndrome (IBS) is a common disorder that affects 10–15% of the
population. Although characterised by a lack of reliable biological markers, the disease state is
increasingly viewed as a disorder of the brain-gut axis. In particular, accumulating evidence points
to the involvement of both the central and peripheral serotonergic systems in disease
symptomatology. Furthermore, altered tryptophan metabolism and indoleamine 2,3-dioxygenase
(IDO) activity are hallmarks of many stress-related disorders. The kynurenine pathway of
tryptophan degradation may serve to link these findings to the low level immune activation recently
described in IBS. In this study, we investigated tryptophan degradation in a male IBS cohort (n =
10) and control subjects (n = 26).
Methods: Plasma samples were obtained from patients and healthy controls. Tryptophan and its
metabolites were measured by high performance liquid chromatography (HPLC) and neopterin, a
sensitive marker of immune activation, was measured using a commercially available ELISA assay.
Results: Both kynurenine levels and the kynurenine:tryptophan ratio were significantly increased
in the IBS cohort compared with healthy controls. Neopterin was also increased in the IBS subjects
and the concentration of the neuroprotective metabolite kynurenic acid was decreased, as was the
kynurenic acid:kynurenine ratio.
Conclusion: These findings suggest that the activity of IDO, the immunoresponsive enzyme which
is responsible for the degradation of tryptophan along this pathway, is enhanced in IBS patients
relative to controls. This study provides novel evidence for an immune-mediated degradation of
tryptophan in a male IBS population and identifies the kynurenine pathway as a potential source of
biomarkers in this debilitating condition.
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Background
Irritable bowel syndrome (IBS) is one of the most com-
monly diagnosed functional bowel disorders [1] and,
while reports of its prevalence vary [2], a reasonable esti-
mate from the literature indicates that it occurs in 10–
15% of the population [3]. A clear understanding of dis-
ease pathophysiology still eludes researchers [4], although
it is increasingly being categorised as a disorder of the
brain-gut axis [5]. Visceral hypersensitivity has received
the most attention as a putative biological marker but its
use as a diagnostic marker is controversial [6] and other
less invasive candidates need to be validated. Accumulat-
ing evidence points to the involvement of both central
and peripheral serotonergic systems in disease symptoma-
thology [7,8]. Serotonin is involved in regulating gastroin-
testinal tract (GIT) secretion, motility and perception
[9,10] and it's role in the regulation of mood is also well
documented [11]. Although much of the attention in the
literature has tended to focus on the conversion of tryp-
tophan to serotonin, the kynurenine pathway actually
represents the dominant metabolic cascade in mammals,
accounting for over 95% of the available peripheral
amino acid [12]. Of late the realisation that the metabo-
lites so generated possess inherent biological activity has
contributed to increased interest in a previously under-
studied area.
The first rate limiting step in the pathway involving the
conversion of tryptophan to kynurenine is catalysed by
either the ubiquitous indoleamine 2,3-dioxygenase
(IDO) or tryptophan 2,3-dioxygenase (TDO) which is
localised to the liver [13]. Kynurenic acid, produced
from kynurenine in a sidearm of the cascade, is a NMDA
receptor antagonist at physiogical concentrations
through its competitive blockade of the glycine co-ago-
nist site [14]. Quinolinic acid, produced along an alter-
native branch of the pathway, has excitotoxic properties
due to potent activation of NR2A and NR2B NMDA
receptor subtypes and its ability to generate free radicals
independently of receptor activation [14]. The activity of
IDO is intertwined with the state of the immune system
and it can be potently induced by cytokines such as inter-
feron-γ , thus providing a mechanism through which
either central or peripheral immune activation can
impact on serotonergic and glutamatergic functionality
[15]. The activity of TDO can be increased by l-tryp-
tophan and it's analogues via an allosteric binding site
and is competitively inhibited by some common
indoleamines including tryptamine [13]. In addition,
the ability of corticosteroids to induce TDO is also well
established [16]. As low level immune activation has
been implicated in IBS [5], the kynurenine pathway of
tryptophan metabolism may represent an key mediator
of the physiological consequences of altered immu-
noregulation in the disease.
This study was performed to assess tryptophan and its
kynurenine pathway metabolites in IBS. Although IBS is
more prevalent in females than males, there is a sizeable
and underappreciated prevalence in male sufferers [2].
Moreover because tryptophan levels are known to fluctu-
ate significantly over the course of the menstrual cycle
[17] we confined our study to a male patient population.
Neopterin, a sensitive marker of immune status [18], has
previously been identified as a marker of disease activity
in inflammatory bowel disease (IBD) [19]. We also meas-
ured this immune marker in this study to identify the
source of any proposed kynurenine pathway alterations.
Methods
Subjects
Twenty-six healthy male control subjects (Mean age 32.2
years, range 20–51 years) and ten male IBS patients (Mean
age 47.5, range 28–65 years) participated in the study.
Patients were diagnosed with IBS based on Rome II crite-
ria, and controls were free from physical illness. The study
was powered to detect differences in analyte levels at the
0.05 level and was approved by an ethics committee
(Research Ethics Committee of the Cork Teaching Hospi-
tals). All subjects provided written, informed consent and
were recruited from a university database of IBS patients.
The database comprised of people who had either
attended gastroenterology clinics at Cork University Hos-
pital or had responded to direct advertisement on the uni-
versity campus or local newspaper regarding participation
in IBS research. Patients also underwent a physical exam-
ination and a full review of clinical history. Healthy con-
trols were recruited from the complement of staff
affiliated to the University College Cork and its teaching
hospitals. All patients and healthy subjects were within
10% of ideal body weight and were free of serotonergic
medications. Two of the patients (20%) and four of the
controls (15.4%) were classified as smokers. All individu-
als were free of transient illness within 2 weeks of study
participation. Venous blood samples were collected in the
morning in tubes with EDTA as anticoagulant after an
overnight fast. The samples were centrifuged (3500RPM,
15 min, 4°C) and the plasma stored at -80°C until
processing.
Reagents
HPLC grade acetonitrile, acetic acid and perchloric acid
were obtained from Alkem/Reagecon (Cork, Ireland). All
other reagents, including the reference metabolites and
internal standard, were obtained from Sigma (Dublin, Ire-
land) unless otherwise stated.
Plasma preparation
Plasma samples were spiked with internal standard (3-
Nitro l-tyrosine) prior to being deproteinised by the addi-
tion of 20 μl of 4 M perchloric acid to 200 μl of sample.
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Samples were centrifuged at 14000 RPM on a Hettich
Mikro 22R centrifuge (AGB, Dublin, Ireland) for 15 min-
utes at 4°C and 100 μl of supernatant transferred to a
HPLC vial for analysis.
Preparation of standards
Stock solutions of each standard were prepared in HPLC
grade water. Working dilutions were prepared from the
stock standards, aliquoted in suitable vials and stored at -
80°C until required for analysis. Standards were acidified
with 20 μl 4 M perchloric acid prior in injection onto the
HPLC system.
HPLC equipment
The HPLC system consisted of a Waters 510 pump
(Waters, Dublin, Ireland) 717plus cooled Autosampler
(Waters), a Hewlett Packard 1046A fluorescent Detector
(Agilent, Dublin, Ireland), a waters 996 photodiode array
(PDA) detector (Waters), a waters bus SAT/IN module
(Waters) and a Croco-Cil column oven (Waters). System
components were used in conjunction with Waters
Empower software. All samples were injected onto a
reversed phase Luna 3 μm C18 (2) 150 × 2 mm column
(Phenomenex, London, England), which was protected
by Krudkatcher disposable pre-column filters (Phenom-
enex) and SecurityGuard cartridges (Phenomenex).
HPLC conditions
The HPLC conditions were modified from a previously
described method [20]. Briefly, the mobile phase con-
sisted of 50 mM acetic acid, 100 mM zinc acetate with 3%
(v/v) acetonitrile and was filtered through Millipore 0.45
μm HV Durapore membrane filters (AGB) and vacuum
degassed prior to use. Compounds were eluted isocrati-
cally over a 30-minute runtime at a flow rate of 0.3 mls/
min after a 20 μl injection. The column was maintained at
a temperature of 30°C and samples/standards were kept
at 8°C in the cooled autoinjector prior to injection. The
fluorescent detector was set at an excitation wavelength of
254 nm and an emission wavelength of 404 nm. The PDA
detector was set to scan between 210–400 nm with chro-
matogram extraction at 330 nm.
Analyte identification and quantitation
L-tryptophan and its metabolites (kynurenine, kynurenic
acid) were identified by their characteristic retention times
as determined by injections of standards which were run
at regular intervals during sample analysis. Concentra-
tions were determined using analyte:internal standard
peak height ratios. Results were expressed as μmol/L of
plasma.
Neopterin ELISA
Neopterin levels in the plasma samples were measured
using a commercially available quantitative enzyme-
linked immunosorbent assay (ELISA) system (IBL, Ham-
burg, Germany). Samples were assayed in duplicate
according to the manufacturers' instructions. The absorb-
ance was read at 450 nm on a Biotek Synergi plate-reader
(Mason, Cork, Ireland) and the results calculated from a
4-parameter logistics curve generated using Gen5 software
(Mason). The assay is sensitive to 0.7 nmol/L with an
intra-assay coefficient of variation of 3.6% and an intra-
assay coefficient of 7.6% at the 7.4 nmol level.
Data Analysis
All data are reported as mean ± SEM. Student's t-tests were
employed to determine differences in analyte levels. Bon-
ferroni corrections for multiple t-tests were employed as
necessary. Correlation analysis between neopterin meas-
ures and the kyn:trp ratio was performed using a Pearson
product-moment correlation. Due to the possibility of their
being an influence of age on the results, we used age as a
covariate assessed by analysis of co-variance (ANCOVA).
Results
Tryptophan and metabolites in IBS patients
There were no differences in plasma l-tryptophan levels
between IBS patients and control subjects (53.37 ± 2.28
vs. 53.32 ± 3.01 μmol/L, p = 0.9826). As shown in figure
1A, l-kynurenine levels were increased in IBS patients rel-
ative to control subjects (3.16 ± 0.29 vs. 2.55 ± 0.12 μmol/
L; t = 2.348, df = 34, p < 0.05) as was the l-kynurenine:l-
tryptophan ratio (0.06058 ± 0.0045 vs. 0.04938 ± 0.0017;
t = 2.820, df = 34, p < 0.01) (Figure 1B). Moreover, as
shown in Figure 2A kynurenic acid concentrations were
decreased in IBS patients compared with control subjects
(0.017 ± 0.002 vs. 0.036 ± 0.003 μmol/L, t = 2.979, df =
30, p < 0.01) as was the kynurenic acid: l-kyurenine ratio
(0.005938 ± 0.0006 vs. 0.01258 ± 0.0007; t = 4.138 df =
39, p < 0.001) (Figure 2B). It should be noted that, for
technical reasons, kynurenic acid could only be quantified
in 6 of the 10 IBS patient samples.
Neopterin Levels
Neopterin Levels were increased in IBS patients relative to
controls (8.406 ± 1.080 vs. 4.250 ± 0.2941 nmol/L, t =
5.129, df = 34, p < 0.0001) (Figure 3A).
Correlation results
There was a significant correlation between neopterin
measures and the L-Kynurenine:l-tryptophan ratio (Figure
3B, P = 0.023, r = 0.7055).
ANCOVA Results
ANCOVA analysis revealed no significant effect of age on
any of the parameters tested.
Discussion
Although some studies have examined kynurenine path-
way metabolites in relation to gastrointestinal function
[21], there is a paucity of reports on tryptophan metabo-
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lism in an IBS population. One of the most interesting
findings in this study was that both plasma kynurenine
levels and the kynurenine:tryptophan ratio were signifi-
cantly increased in the male IBS cohort compared to
healthy control subjects. Although there is considerable
group overlap between tryptophan and kynurenine, the
ratio is considered a more appropriate indicator of the
degree of tryptophan degradation along this pathway than
absolute measurement of its components [22]. The fact
that both kynurenine and the ratio were increased in the
subjects tested is compelling evidence of increased activity
of the enzymes responsible for tryptophan breakdown in
this patient population and has many possible ramifica-
tions. The decreased peripheral availability of tryptophan
could impact on central uptake and affect serotonin syn-
thesis [13]. Indeed this hypothesis is supported by acute
tryptophan depletion studies, whereby, through a dietary
intervention which limits the central availability of tryp-
tophan, a state of reduced serotonin synthesis, metabo-
lism and release is induced. Moreover, these studies have
been recently employed to demonstrate a dysfunctional
serotonergic system in IBS [3,23]. It is, however, difficult
to relate acutely altered tryptophan levels in those studies
to the apparent chronic disturbances in the tryptophan
metabolic pathway noted here. While we failed to detect
any alteration in actual tryptophan levels in the current
studies, which may lead one to suggest that the relevance
of the increased breakdown may be physiologically ques-
tionable, the impact of increased kynurenine levels needs
to be factored in to the interpretation of these results.
Kynurenine and tryptophan enter the central nervous sys-
tem (CNS) via the same transport mechanism [14] and
the increased competition at this transporter should
restrict tryptophan uptake into the CNS. The conse-
quences of increased peripheral tryptophan breakdown
also need to be considered, since it is unlikely that an
A/B: (A) Plasma kynurenine Levels (μmol/L) in healthy con-trols and male IBS pati ts and (B) Kynurenine:tryptopha  ratio in healthy controls and male IBS patientsFigure 1
A/B: (A) Plasma kynurenine Levels (μmol/L) in 
healthy controls and male IBS patients and (B) 
Kynurenine:tryptophan ratio in healthy controls and 
male IBS patients.
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increased rate of breakdown would solely impact on cen-
tral serotonin production per se.
In the gastrointestinal tract serotonin has a role in visceral
sensation and pain transmission [24] and pharmacologi-
cal agents acting at these receptors, including alosetron (5-
HT3 antagonist) and tegaserod (5-HT4 agonist), have been
shown to modulate intestinal transit [25]. Whether the
alterations described in this study could have a physiolog-
ically relevant impact on enteric serotonergic signalling
has not yet been confirmed but remains an interesting
possibility. Whilst it is conceivable that the increased
kynurnenine:tryptophan ratio originates in the increased
activity of hepatic TDO, the alternative scenario of
increased IDO activity is equally, if not more, plausible.
The elevated neopterin levels in the IBS cohort strongly
suggest that IDO is the main enzymatic player. Although
the majority of the neopterin measurements were below
the 10 nmol level, which is considered to be reliably indic-
ative of a disease state [26], they do confirm, at the very
least, a low level immune activation in the male IBS
group. Of interest is that the statistical difference between
the groups is much greater for this measure than for the
tryptophan indices. This may be due to the fact that while
neopterin is considered to be a general marker of immune
activation, IDO is only activated by specific immune
agents [13]. While we cannot conclusively say that there is
an increased central tryptophan degradation from our
peripheral measures our conclusions are in line with that
of Saito et al. [16] who previously demonstrated increased
IDO activity both peripherally and centrally following sys-
temic immune stimulation. Because elevated IDO activity
could further impact on both central and peripheral sero-
tonergic transmission through its ability to metabolise
serotonin [27], if IDO is activated, the knock-on conse-
quences for serotonergic signalling are greater than if it is
TDO-mediated. In this regard, the sensitive and reliable
measurement of interferon-γ  levels, which were below the
limit of quantitation (LOQ) of the analysis method
employed in the current samples (unpublished data),
would be most useful in future studies to further assess
immune activation and confirm IDO activation in IBS
cohorts [26]. Our results also show decreased plasma
kynurenic acid levels as well as a decrease in the kynurenic
acid:kynurenine ratio. This ratio is sometimes termed the
neuroprotective ratio and essentially indicates a decreased
conversion of kynurenine to kynurenic acid [28]. In the
current studies, kynurenic acid could only be determined
in six out of ten of the IBS population. However, a coinci-
dental increase due to low statistical power is unlikely due
to the decrease in both kynurenic acid and the kynurenic
acid:kynurenine ratio.
It is tempting to suggest that these data represents a shunt-
ing of tryptophan away from the kynurenic acid branch
and towards the preferential formation of the neurotoxic
metabolite but we did not measure quinolinic acid in this
study and, therefore, cannot conclusively say that this is
indeed the case. The ability of quinolinic acid to activate
both central and peripheral glutamatergic transmission
could greatly impact on gastrointestinal function.
While these results suggest that the routine measurement
of tryptophan pathway metabolites in IBS patients may
provide biomarkers of the disease state a number of study
limitations need to be considered before coming to this
conclusion. The exclusively male patient population in
this study was relatively small in size so that further sub-
group analysis of the results according to disease status,
type or symptom severity was not practical. Consequently,
we cannot assign the observed alteration to diarrhoea pre-
dominant, constipation predominant or alternating
symptoms. Neither can we say that the alterations are
A/B: (A) Plasma neopterin levels (nmol/L) in healthy controls and male IBS p ti ntsFigure 3
A/B: (A) Plasma neopterin levels (nmol/L) in healthy 
controls and male IBS patients.(B)Correlation 
between neopterin levels and the kyn:tryp ratio 
(Pearson product-moment correlation, *p < 0.05, r = 
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indicative of an active or quiescent phase of the disease.
The study could also be criticised for its reliance on male
IBS samples. However, it should be pointed out that,
although IBS is more prevalent in the female population,
a significant number of male patients present with the
condition [2]. In addition, the measurement of tryp-
tophan levels in a female population can be complicated
by variations over the course of the menstrual cycle [17].
In any case, the results strongly suggest that a future
expanded study should be conducted that would allow a
more detailed analysis of the biomarker potential of the
tryptophan metabolites.
Conclusion
In summary, we have identified alterations in key indices
of tryptophan metabolism in a male IBS population
which are attributable to immune activation. We suggest
that when used in conjunction with neopterin measures,
they may be useful as a potential biomarker panel in IBS.
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